Drug safety evaluation of naltrexone/bupropion for the treatment of obesity

Author： Verpeut Jessica L   Bello Nicholas T  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.13, Iss.6, 2014-06, pp. : 831-841

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

By Plodkowski Raymond A   Nguyen Quang   Sundaram Umasankari   Nguyen Loida   Chau Diane L   St Jeor Sachiko  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 1069-1081

Informa Healthcare

Access to resources Recommend Favorite

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR

By  

Drugs in R&D, Vol. 10, Iss. 1, 2010-05 ,pp. : 25-32

Adis International

Access to resources Recommend Favorite

Drug safety evaluation of zonisamide for the treatment of epilepsy

By Zaccara Gaetano   Tramacere Luciana   Cincotta Massimo  

Expert Opinion on Drug Safety, Vol. 10, Iss. 4, 2011-07 ,pp. : 623-631

Informa Healthcare

Access to resources Recommend Favorite

Drug safety evaluation of vemurafenib in the treatment of melanoma

By Tsai Kenneth Y   Nowroozi Sasan   Kim Kevin B  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 767-775

Informa Healthcare

Access to resources Recommend Favorite

Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity

By Ioannides-Demos Lisa L.  

Drug Safety, Vol. 29, Iss. 4, 2006-01 ,pp. : 277-302

Adis International

Access to resources Recommend Favorite